AntiEGFR-G6-COOH dendrimers loaded with erlotinib to improve its drug resistance and anticancer effi

来源 :The 6th International Conference on Nanoscience and Technolo | 被引量 : 0次 | 上传用户:dacong966963
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Erlotinib is an-EGFR-specific TKI that functiones as an antiproliferative agent and is an inducer of apoptosis and reversible cell cycle arrest[1].
其他文献
Near-infrared plasmonic nanoparticles demonstrate great potential in disease theranostic applications.
The insufficient cellular uptake of nanocarriers and their slow drug release have become major obstacles for achieving satisfactory anticancer outcomes in nano-medicine therapy.
The human mutT homologue MTH1,a nucleotide pool sanitizing enzyme,represents a vulnerability factor and an attractive target for anticancer therapy.
Although many multifunctional drug-loaded nanomaterials have been designed to increase drug delivery into tumor cells,only limited improvement has been achieved to overcome multi-layered stromal cell
Purpose-Peptides have emerged as promising cancer therapeutics characterized by low toxicity,high specificity,and ease of synthesis.The short half-life of peptide therapeutics stands as the most chall
Highly crosslinked proteins,including keratin and soyprotein containing 7%and 1.2%of cysteine respectively,were electrospun into three-dimensional(3D)ultrafine fibrous scaffolds for biomedical applica
Previous studies mainly attributed the improved anti-tumor effect of nanocarriers-based drug delivery systems to its favorable pharmacokinetics,specific tumor targeting and drug accumulation in tumor
We have synthesised a range of novel protein-polymer surfactant nanoconjugates by systematic surface modification.Using dynamic light scattering and UV-visible spectroscopy we have demonstrated that t
Polymeric nanoparticle coated with intact red blood cell(RBC)membrane has emerged as biomimetic toxin nanosponges that absorb membrane-damaging toxins and divert them away from their cellular targets.
An amphiphilic hyaluronic acid derivate,redox-sensitive hyaluronic acid-deoxycholic acid(HA-ss-DOCA)conjugate,was successfully developed.